KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers
暂无分享,去创建一个
J. Furuse | Y. Ohkura | H. Ohnishi | Takashi Watanabe | M. Sugiyama | Toshiyuki Mori | S. Matsushima | K. Ohtsuka | M. Yokoyama
[1] D. Geynisman,et al. Toward personalized treatment of advanced biliary tract cancers. , 2012, Discovery medicine.
[2] J. L. Tang,et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Zullo,et al. Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time , 2012, Journal of Gastrointestinal Cancer.
[5] T. Cenci,et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? , 2011, Clinical colorectal cancer.
[6] J. M. Xie,et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[7] M. Tzardi,et al. Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients , 2011, PloS one.
[8] Razelle Kurzrock,et al. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.
[9] L. Macconaill,et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma , 2011, BMC Cancer.
[10] Xiao-dong Zhu,et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. , 2010, European journal of cancer.
[11] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[12] A. Zhu,et al. Genetics of biliary tract cancers and emerging targeted therapies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Bardelli,et al. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Bardelli,et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas , 2010, BMC Cancer.
[15] J. Meyerhardt,et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.
[16] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[17] M. Olschewski,et al. EGFR and HER2 expression in advanced biliary tract cancer. , 2008, World journal of gastroenterology.
[18] T. Takada,et al. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. , 2009, Journal of hepato-biliary-pancreatic surgery.
[19] F. Siannis,et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.
[20] S. Reed,et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. , 2007, Cancer research.
[21] M. Makuuchi,et al. Report of the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan † , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[22] T. Goya,et al. A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non–small-cell Lung Carcinoma , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[23] K. McGlynn,et al. A Comparison of Trends in the Incidence of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.
[24] C. la Vecchia,et al. Gallbladder cancer worldwide: Geographical distribution and risk factors , 2006, International journal of cancer.
[25] H. Fujii,et al. Amplification and overexpression of c‐erbB‐2, epidermal growth factor receptor, and c‐met in biliary tract cancers , 2005, The Journal of pathology.
[26] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] I. Ellis,et al. Best Practice No 176 , 2004, Journal of Clinical Pathology.
[28] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[29] A. Rashid,et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] W. H. Kim,et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. , 2001, Cancer letters.
[31] M. Gnant,et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] T. Itoi,et al. Histological and genetic changes in malignant transformation of gallbladder adenoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.